WO2003038063A3 - Human secreted proteins - Google Patents

Human secreted proteins Download PDF

Info

Publication number
WO2003038063A3
WO2003038063A3 PCT/US2002/008277 US0208277W WO03038063A3 WO 2003038063 A3 WO2003038063 A3 WO 2003038063A3 US 0208277 W US0208277 W US 0208277W WO 03038063 A3 WO03038063 A3 WO 03038063A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
present
human secreted
polynucleotides
encompassed
Prior art date
Application number
PCT/US2002/008277
Other languages
French (fr)
Other versions
WO2003038063A2 (en
Inventor
Craig A Rosen
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to EP02799146A priority Critical patent/EP1390390A4/en
Priority to CA002441755A priority patent/CA2441755A1/en
Priority to AU2002363296A priority patent/AU2002363296A1/en
Publication of WO2003038063A2 publication Critical patent/WO2003038063A2/en
Publication of WO2003038063A3 publication Critical patent/WO2003038063A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating hematopoietic and hematologic diseases, disorders, and/or conditions related thereto. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
PCT/US2002/008277 2001-03-21 2002-03-19 Human secreted proteins WO2003038063A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02799146A EP1390390A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
CA002441755A CA2441755A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002363296A AU2002363296A1 (en) 2001-03-21 2002-03-19 Human secreted proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US60/277,340 2001-03-21
US30617101P 2001-07-19 2001-07-19
US60/306,171 2001-07-19
US33128701P 2001-11-13 2001-11-13
US60/331,287 2001-11-13

Publications (2)

Publication Number Publication Date
WO2003038063A2 WO2003038063A2 (en) 2003-05-08
WO2003038063A3 true WO2003038063A3 (en) 2003-12-11

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
PCT/US2002/008276 WO2002076488A1 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008279 WO2002090526A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008278 WO2002102994A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008123 WO2002102993A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008277 WO2003038063A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
PCT/US2002/009785 WO2002095010A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008124 WO2003004622A2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PCT/US2002/008276 WO2002076488A1 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008279 WO2002090526A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008278 WO2002102994A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008123 WO2002102993A2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2002/009785 WO2002095010A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008124 WO2003004622A2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Country Status (4)

Country Link
EP (7) EP1414845A4 (en)
AU (6) AU2002354719A1 (en)
CA (7) CA2441840A1 (en)
WO (7) WO2002076488A1 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
EP1000084A4 (en) 1997-07-08 2003-03-26 Human Genome Sciences Inc 123 human secreted proteins
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ATE437947T1 (en) 1998-06-01 2009-08-15 Agensys Inc SERPENT TRANS MEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCER AND THEIR USES
MXPA01007163A (en) 1999-01-15 2002-03-27 Biogen Inc Antagonists of tweak and of tweak receptor and their use to treat immunological disorders.
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002048370A2 (en) 2000-10-31 2002-06-20 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
WO2002083921A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
JP2005505271A (en) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド Nucleic acids and corresponding proteins given the name STEAP-1 useful in the treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JPWO2003033727A1 (en) 2001-10-12 2005-02-03 山之内製薬株式会社 Cell death inhibitor screening method
NZ548701A (en) 2002-04-09 2008-03-28 Biogen Idec Inc Methods for treating tweak-related conditions
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2007506433A (en) * 2003-09-23 2007-03-22 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and compositions for correlating single nucleotide polymorphisms in the vitamin K epoxide reductase gene with warfarin dose
PT2189523E (en) * 2003-10-14 2012-01-24 Baxter Healthcare Sa Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
WO2005076003A2 (en) * 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113601A2 (en) 2004-04-22 2005-12-01 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
KR101268877B1 (en) 2004-09-01 2013-05-31 다이나박스 테크놀로지 코퍼레이션 Methods and compositions for inhibition of innate immune responses and autoimmunity
WO2006026807A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents for treatment or prevention of an allergic disorder
JP2008512100A (en) * 2004-09-07 2008-04-24 テレソン インスティテュート フォー チャイルド ヘルス リサーチ Method for diagnosis and / or prediction of onset of allergic diseases
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
MX349285B (en) 2005-02-28 2017-07-20 Baxalta Inc Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression.
JP2008532544A (en) 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and compositions for producing active vitamin K-dependent proteins
ES2432564T3 (en) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Treatment and evaluation of inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
GB2470843B (en) * 2005-09-01 2011-04-13 Florey Howard Inst Models and methods for the assessment of potential therapeutic agents for the modulation of NDFIP1-NEDD4 interactions
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CA2667019C (en) 2006-10-27 2016-03-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US20100136028A1 (en) 2006-11-07 2010-06-03 Sparrow Carl P Antagonists of pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2008118386A2 (en) 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
WO2009055076A2 (en) 2007-10-26 2009-04-30 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
EP2215268B1 (en) * 2007-11-30 2018-08-29 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
JP2013509194A (en) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション AX213 and AX132PCSK9 antagonists and variants
AU2010313381A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
CA2802873C (en) 2010-06-16 2018-09-18 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
GEP20156313B (en) 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina Methods and compositions for producing active vitamin k-dependent proteins
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
CN104321333A (en) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN110352242A (en) 2016-12-23 2019-10-18 哈佛大学的校长及成员们 The gene editing of PCSK9
BR112019018767A2 (en) 2017-04-03 2020-05-05 Hoffmann La Roche antibodies, bispecific antigen binding molecule, one or more isolated polynucleotides, one or more vectors, host cell, method for producing an antibody, pharmaceutical composition, uses, method for treating a disease in an individual and invention
ES2963042T3 (en) 2017-06-22 2024-03-25 Procter & Gamble Films that include a water-soluble layer and an organic vapor-deposited coating
EP3642383B1 (en) * 2017-06-22 2022-12-21 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (en) * 1996-02-02 1999-12-15 나까니시 히로유끼 A pharmaceutical preparation containing a human growth hormone
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins
JP2002520050A (en) * 1998-07-15 2002-07-09 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 71 human secreted proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides
US6174994B1 (en) * 1997-05-30 2001-01-16 Smithkline Beecham Corporation 7TM receptor (H2CAA71)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1390390A4 *

Also Published As

Publication number Publication date
EP1390390A4 (en) 2009-07-08
EP1414845A2 (en) 2004-05-06
EP1404702A4 (en) 2009-07-08
WO2003004622A2 (en) 2003-01-16
WO2002076488A1 (en) 2002-10-03
WO2002090526A3 (en) 2003-10-30
WO2002102994A2 (en) 2002-12-27
EP1404702A2 (en) 2004-04-07
CA2441417A1 (en) 2002-11-14
WO2002102993A2 (en) 2002-12-27
EP1381622A2 (en) 2004-01-21
AU2002332391A1 (en) 2003-01-02
WO2002095010A2 (en) 2002-11-28
CA2441416A1 (en) 2003-01-16
CA2441702A1 (en) 2002-12-27
EP1414845A4 (en) 2009-07-08
AU2002326293A1 (en) 2003-01-02
CA2441832A1 (en) 2002-12-27
WO2002090526A2 (en) 2002-11-14
EP1379132A4 (en) 2009-07-01
CA2441397A1 (en) 2002-10-03
WO2003038063A2 (en) 2003-05-08
EP1379264A4 (en) 2009-07-08
AU2002320013A1 (en) 2002-11-18
CA2441840A1 (en) 2002-11-28
WO2002102993A3 (en) 2004-03-25
WO2003004622A3 (en) 2004-02-19
EP1379264A1 (en) 2004-01-14
WO2002095010A3 (en) 2004-02-12
AU2002363296A1 (en) 2003-05-12
AU2002324424A1 (en) 2002-12-03
EP1379132A2 (en) 2004-01-14
WO2002102994A3 (en) 2003-07-24
AU2002354719A1 (en) 2003-01-21
CA2441755A1 (en) 2003-05-08
EP1423134A2 (en) 2004-06-02
EP1390390A2 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
WO2003038063A3 (en) Human secreted proteins
WO2002092787A3 (en) Human secreted proteins
WO2001055364A3 (en) Nucleic acids, proteins, and antibodies
WO2001090304A3 (en) Nucleic acids, proteins, and antibodies
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO2001055306A3 (en) Nucleic acids, proteins, and antibodies
WO2004042000A3 (en) 157 human secreted proteins
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO2002072763A3 (en) Nucleic acids, proteins, and antibodies
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
WO2001055305A8 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2441755

Country of ref document: CA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002799146

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002799146

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP